#androgen blocker

After 15 years, survival rates were similar for patients who were treated promptly and those who opted for active monitoring.

Blogger Daniel Zeller makes assessments after completing salvage radiation and hormone therapies for his prostate cancer.

Melanoma, a potentially deadly type of skin cancer, is often more fatal in men than women. Androgen receptors may play a role.

People with prostate cancer who received hormone therapy plus pelvic lymph node treatment experienced an average five-year survival of 87%.

A large clinical trial found that adding darolutamide to two other therapies increased survival for people with advanced prostate cancer.

In a nutshell, he suggested doing concurrent androgen deprivation (hormone) therapy with the salvage radiation.

Study finds bone health testing for patients with prostate cancer undergoing ADT therapy are not meeting guideline recommendations.

The androgen receptor inhibitor delayed cancer metastasis in a late-stage clinical trial.

The American Society of Clinical Oncology has released new prostate cancer guidelines.